Citigroup Maintains Buy on Protagonist Therapeutics, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 76.6%

Neg 0% Neu 0% Pos 76.6%

Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $115 to $125.